Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3656)
All Articles published online
|
Jun 7, 2012 (publication date) through Nov 21, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Nishizawa T, Suzuki H, Maekawa T, Harada N, Toyokawa T, Kuwai T, Ohara M, Suzuki T, Kawanishi M, Noguchi K, Yoshio T, Katsushima S, Tsuruta H, Masuda E, Tanaka M, Katayama S, Kawamura N, Nishizawa Y, Hibi T, Takahashi M. Dual therapy for third-line |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v18/i21/2735.htm |
| Number | Citing Articles |
| 1 |
Anthony O'Connor, Javier Molina‐Infante, Javier P. Gisbert, Colm O'Morain. Treatment of Helicobacter pylori Infection 2013. Helicobacter 2013; 18(s1): 58 doi: 10.1111/hel.12075
|
| 2 |
Sheila López-Góngora, Ignasi Puig, Xavier Calvet, Albert Villoria, Mireia Baylina, Neus Muñoz, Jordi Sanchez-Delgado, David Suarez, Victor García-Hernando, Javier P. Gisbert. Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment forHelicobacter pyloriinfection. Journal of Antimicrobial Chemotherapy 2015; 70(9): 2447 doi: 10.1093/jac/dkv155
|
| 3 |
Toshihiro Nishizawa, Takama Maekawa, Noriko Watanabe, Naohiko Harada, Yasuo Hosoda, Masahiro Yoshinaga, Toshiyuki Yoshio, Hajime Ohta, Syuuji Inoue, Tatsuya Toyokawa, Haruhiro Yamashita, Hiroki Saito, Toshio Kuwai, Shunsuke Katayama, Eiji Masuda, Hideharu Miyabayashi, Toshio Kimura, Yuko Nishizawa, Masahiko Takahashi, Hidekazu Suzuki. Clarithromycin Versus Metronidazole as First-line Helicobacter pylori Eradication. Journal of Clinical Gastroenterology 2015; 49(6): 468 doi: 10.1097/MCG.0000000000000165
|
| 4 |
Ju Yup Lee, Nayoung Kim, Ryoung Hee Nam, Soo In Choi, Jung Won Lee, Dong Ho Lee. Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018. Helicobacter 2019; 24(6) doi: 10.1111/hel.12660
|
| 5 |
György Miklós Buzás. Helicobacter pylori – 2012. Orvosi Hetilap 2012; 153(36): 1407 doi: 10.1556/OH.2012.29443
|
| 6 |
Toshihiro Nishizawa, Kosuke Sakitani, Hidekazu Suzuki, Shuntaro Yoshida, Yosuke Kataoka, Yousuke Nakai, Hirotoshi Ebinuma, Takanori Kanai, Osamu Toyoshima, Kazuhiko Koike. Clinical features of cardiac nodularity-like appearance induced by <i>Helicobacter pylori</i> infection. World Journal of Gastroenterology 2020; 26(35): 5354-5361 doi: 10.3748/wjg.v26.i35.5354
|
| 7 |
Toshihiro Nishizawa, Hidekazu Suzuki, Ai Fujimoto, Hiroto Kinoshita, Shuntaro Yoshida, Yoshihiro Isomura, Akira Toyoshima, Takanori Kanai, Naohisa Yahagi, Osamu Toyoshima. Effects of patient age and choice of antisecretory agent on success of eradication therapy for <i>Helicobacter pylori</i> infection. Journal of Clinical Biochemistry and Nutrition 2017; 60(3): 208 doi: 10.3164/jcbn.16-86
|
| 8 |
Jason Ferreira, Steven F. Moss. Current Paradigm and Future Directions for Treatment of Helicobacter pylori Infection. Current Treatment Options in Gastroenterology 2014; 12(4): 373 doi: 10.1007/s11938-014-0027-6
|
| 9 |
Hidekazu Suzuki, Hideki Mori. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. Journal of Gastroenterology 2018; 53(3): 354 doi: 10.1007/s00535-017-1407-1
|
| 10 |
Toshihiro Nishizawa, Hidekazu Suzuki, Masahiko Takahashi, Masayuki Suzuki, Toshifumi Hibi. Delay of second‐line eradication therapy for Helicobacter pylori can increase eradication failure. Journal of Gastroenterology and Hepatology 2013; 28(10): 1608 doi: 10.1111/jgh.12281
|
| 11 |
Toshihiro Nishizawa, Hidekazu Suzuki. Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing. Frontiers in Molecular Biosciences 2014; 1 doi: 10.3389/fmolb.2014.00019
|
| 12 |
Hideki Mori, Hidekazu Suzuki, Juntaro Matsuzaki, Hitoshi Tsugawa, Seiichiro Fukuhara, Sawako Miyoshi, Kenro Hirata, Takashi Seino, Misako Matsushita, Tatsuhiro Masaoka, Takanori Kanai. Efficacy of 10‐day Sitafloxacin‐Containing Third‐Line Rescue Therapies for Helicobacter pylori Strains Containing the gyrA Mutation. Helicobacter 2016; 21(4): 286 doi: 10.1111/hel.12286
|
| 13 |
Osamu Toyoshima, Toshihiro Nishizawa, Kazuhiko Koike. Endoscopic Kyoto classification of <i>Helicobacter pylori</i> infection and gastric cancer risk diagnosis. World Journal of Gastroenterology 2020; 26(5): 466-477 doi: 10.3748/wjg.v26.i5.466
|
| 14 |
Miao Duan, Jing Liu, Xiuli Zuo. Dual therapy for Helicobacter pylori infection. Chinese Medical Journal 2023; doi: 10.1097/CM9.0000000000002565
|
| 15 |
Takahisa Furuta, Mihoko Yamade, Tomohiro Higuchi, Satoru Takahashi, Natsuki Ishida, Shinya Tani, Satoshi Tamura, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Ken Sugimoto. Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori. Journal of Clinical Medicine 2023; 12(9): 3110 doi: 10.3390/jcm12093110
|
| 16 |
Toshihiro Nishizawa, Munkhbayar Munkjargal, Hirotoshi Ebinuma, Osamu Toyoshima, Hidekazu Suzuki. Sitafloxacin for Third-Line Helicobacter pylori Eradication: A Systematic Review. Journal of Clinical Medicine 2021; 10(12): 2722 doi: 10.3390/jcm10122722
|